Publikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (9)

2024

  1. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

    Blood

  2. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

    Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321

2022

  1. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

    Leukemia, Vol. 36, Núm. 5, pp. 1432-1435

  2. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

    Blood

2021

  1. Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

    American Journal of Hematology

  2. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436

  3. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    Leukemia, Vol. 35, Núm. 3, pp. 835-849

2020

  1. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151